Clinical Trial Update: A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab [Phase 3]

View source ↗

Summary

Phase 3 study evaluating risankizumab in adults with plaque psoriasis who had suboptimal response to secukinumab or ixekizumab; study completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2023-03-21